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Chapter 10
SUMMARY AND GENERAL DISCUSSION
Since the discovery and development of the artificial kidney by Willem Kolff (1) it is possible to 
treat patients with end-stage chronic kidney disease. However, dialysis is associated with an 
high rate of morbidity and mortality (2), therefore the preferred treatment for end-stage chronic 
kidney disease is kidney transplantation for those in good enough health (3). Worldwide, the 
majority of donated kidneys are retrieved from deceased donors. Unfortunately organs from 
these donors are associated with inflammation (4), reactive oxygen species induced injury 
(5,6), and mitochondrial dysfunction (7,8), eventually resulting in inferior transplant outcomes 
when compared to kidneys derived from living donors (9,10). To decrease the mortality for 
patients with end-stage renal disease and improve the outcomes of kidney transplantation 
the number of available donor organs has to be increased and the quality of those donor 
organs has to be improved. Because there is a severe shortage of donor organs, the transplant 
community turns to organs from donors who were previously considered not suitable for 
transplantation. These extended criteria donor organs are associated with inferior transplant 
outcomes and therefore a high percentage of these organs are not used (11). By understanding 
the mechanism that affects the organ quality a better and more objective decision could be 
made for what donor organs should be considered for transplantation, hopefully decreasing 
the unnecessary discard of potential grafts. A better insight what happens to the graft quality 
in the harmful environment of the deceased donor could lead to new treatment strategies to 
improve the graft survival of these suboptimal quality organs. One strategy to improve the 
graft quality is by increasing the expression of protective proteins prior to, or early during, the 
infliction of transplant-related injury. 
Chapter 2 reviews the protective properties of heat shock proteins in organ transplantation. 
The working mechanism from the family of heat shock proteins (HSPs) is explained on the 
intracellular level and their potential immune activating properties on the extracellular 
level. The detrimental effects occurring during organ donation and transplantation bring for 
opportunities to treat the donor. In the last part of this chapter we present the evidence for 
organ protection after heat shock protein upregulation. The evidence for protection against 
ischaemia reperfusion injury after treating the animals with HSP-inducing compounds is 
plenty, however there are no studies published about treating the deceased donor with HSF-
1 inducible heat shock proteins. Protective effects have been found with transplantation of 
brain dead donor kidneys after HO-1 upregulation (12,13). Recently the results of a phase-II 
trials have been published on recipient treatment with the HO-1 inducing compound Hemin 
(14). Administration of this compound at the early onset of brain death could be a promising 
strategy to improve the graft quality and transplant outcomes.
In Chapter 3 we assessed the effect of brain death-related stress on the renal expression of 
heat shock proteins in an animal model. Here we show that after four hours the expression of 
stress proteins HO-1 and HSP-A1A are predominantly upregulated. In this chapter we show that 
the amount of HSPA1A upregulation is also associated with those of other heat shock proteins 
regulated by the same protein, HSF-1. Transplantation of kidneys procured from deceased 
donors have inferior outcomes compared to those from living donors, thus we believe this 
protective and recuperative response is not sufficient.
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In Chapter 4 pre-treatment with the heat shock protein boosting compound 
geranygeranylacetone was used to improve the renal graft quality after deceased brain dead 
organ donation. Brain death-related injury does not induce histological changes within the 
four-hour period of this model, therefore the effect of treatment was objectified by assessing 
pro-inflammatory changes. Geranylgeranylacetone treatment decreased the expression of 
one of the most potent cytokines, interleukin-6. However, no effect of geranylgeranylacetone 
treatment was seen on the renal expression of heat shock proteins. 
In Chapter 5 the brain dead donor was treated with a more potent heat shock protein boosting 
compound derived from geranylgeranylacetone. Pre-treatment of rats with Nyk9354 induced 
renal expression of heat shock protein HSPA1A and inhibited the expression of interleukin-6, 
adhesion molecules (E-selectin and ICAM-1), and the influx of leukocytes. However, in this study 
we only assessed surrogate markers for the quality of the kidney since no transplantation was 
performed to determine the effect of heat shock protein upregulation on the long-term kidney 
function. As reviewed in chapter 2 the induction of HSPA1A is protective for ischaemia and 
reperfusion injury, even if geranylgeranylacetone is administered after the initial ischaemic 
insult (15). In our view treatment with Nyk9354 is a promising approach to prevent pro-
inflammatory changes in the donor and improve the renal graft quality. To implement a 
compound like Nyk9354 into the clinical practice the first logical study would be to test this in 
a deceased brain dead transplant model.
In Chapter 6 we review the literature in a systematic fashion for the evidence of donor 
treatment on short- and longer term graft outcomes in transplantation for organs procured 
from deceased donors. We show that the amount of studies published on donor treatment is 
limited and the evidence is in general fairly poor. From this systematic review we could conclude 
that there is no strong evidence of a protective effect from a single strategy on the long-term 
graft- or patient survival after transplantation of deceased donor derived organs. In this review 
we only focussed on treatment of the donor, however, with the rise of the machines for organ 
preservation there is also a possibility to treat the graft. This treatment possibility was not 
reviewed but it could be a window of opportunity to improve the quality of the graft.
In Chapter 7 we induced 45 minutes of ischaemia to the kidney and evaluated the effects 
of reperfusion injury after four and 24 hours. Mass spectrometry was used to evaluate the 
effects of this injury mechanism on the protein and metabolite level. We show that ischaemia 
reperfusion injury impairs mitochondria and the cell energy metabolism, forcing the kidney 
cells to switch their energy source to consuming more lipids. However, lipids can be toxic to 
the cell (16,17) and might therefore not be the optimal energy source during transplantation.
Although only two time point were investigated, the changes observed are in accordance with 
other studies that also show enhanced lipid utilisation after ischaemia (18). As is reviewed in 
the previous chapter, there is currently no strong evidence that a single treatment strategy 
of the donor will benefit the organ and its functions after transplantation. Therefore, it is 
necessary to gain a better insight what is occurring in the deceased donor and during ischaemia 
reperfusion that affects the graft. These insights might lead to new treatment options. What 
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has become apparent from this chapter and the mass spectrometry work done in a deceased 
brain dead model (7) is that mitochondrial dysfunction occurs in the donor organ. Treating this 
cell organelle could enhance the energy metabolism and the cellular functions of the graft.
In Chapter 8 we used mass spectrometry to assess what changes occur in the kidney during 
brain death. To investigate this effect, kidney biopsies from human kidney donors were 
grouped according to the outcome after kidney transplantation. Here we show that kidneys 
with a good transplant outcome have higher levels of anti-oxidants, while kidneys with a 
poor transplant outcome show higher expression levels of pro-inflammatory proteins. In this 
study we show that the changes that occur during brain death are associated with the graft 
function after transplantation. To implement a diagnostic tool for a molecular based donor 
risk index these results first have to be further validated. The cohort size for this study is 
limited and ideally these results should be confirmed in a very large cohort where donors were 
not preselected for transplant outcomes, something that is now possible with the national 
collection of kidney biopsies in the UK QUOD biobank. Furthermore, these results show the 
relevance of anti-oxidants in kidney transplantation, a pre-treatment approach that has shown 
to be protective in the donor and recipient (19).
Determination of the molecular profile of the donor kidney is associated with the graft 
function after transplantation, but it would be more elegant if blood could be used as a tool 
for graft quality assessment. Blood can be retrieved from the donor at multiple and earlier 
time points, and the organ does not become injured to obtain a biopsy. In Chapter 9 we used 
mass spectrometry to assess the effect of long-term blood storage at room temperature 
on the sample quality for proteomic analysis. Here we show that storage of blood at room 
temperature for two days still produces good quality proteomics data for discovery study 
purposes. Therefore, we believe that it is feasible to screen blood of deceased organ donors 
for biomarkers, even though candidate samples have been stored at room temperature 
for variable times before long-term storage. After an initial discovery approach with mass 
spectrometry, validation usually occurs with enzyme-linked immunosorbent assays (ELISA). 
We did not validate if longer storage at room temperature affects those assays. Although we 
observed only limited enzymatic cleavage and protein degradation, validation techniques 
should be validated first before use on samples with variable storage times.
FUTURE PERSPECTIVES
The results of this thesis give further direction for new research projects to improve the 
outcome of deceased donor kidney transplantation. The potential of distinguishing between 
good and suboptimal donors could aid the physician with the decision of accepting or declining 
a kidney for transplantation. There is a high need for biomarkers or surrogate markers of 
graft quality and thus far there has not been a single biomarker that could help to predict 
graft quality. A panel of biomarkers indicating what protective and detrimental pathways 
are activated would be in our view the most feasible approach to develop a molecular donor 
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risk index score. Discovered biomarkers should be tested in a large and multicentre cohort, 
a possibility that has now been established by the QUOD biobank in the UK. Instead of using 
kidney biopsies it would be elegant if blood could be used for biomarker discovery, as this is an 
easy to obtain sample that could be analysed before the start of organ procurement. 
The two protective agents, geranylgeranylacetone and Nyk9354 have been tested as a treatment 
of the donor. We conclude that there is no role for geranylgeranylacetone as treatment of the 
donor, however Nyk9354 enhanced the expression of the cytoprotective protein HSPA1A and 
inhibited to some extent the inflammation in the donor kidney. Upregulation of HSPA1A should 
be further explored before commencing a human trial. Apart from donor treatment, the graft 
can also be treated ex-situ during hypothermic or even normothermic machine perfusion. 
Administration of cytoprotective agents like anti-oxidants or heat shock protein boosting 
compounds could be a potential treatment strategy to protect the graft quality during the 
process of organ preservation and transplantation.
CONCLUSION
Heat shock proteins play an important role in kidney transplantation. Deceased organ donation 
is associated with upregulation of the heat shock proteins HSPA1A and HO-1. Enhancing the 
expression of HSPA1A improves the graft quality of the procured deceased brain dead donor 
kidney. Other associations for a good functioning graft are low levels of pro-inflammatory 
proteins and high levels of anti-oxidants. In randomised clinical trials the effect of innate 
immune system inhibition and anti-oxidant administration should be explored to improve 
allograft outcome after kidney transplantation.
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